![Ceftriaxone [Rocephin] – (Antibiotic for Severe UTI and Pyelonephritis)](data:image/svg+xml,%3Csvg%20xmlns='http://www.w3.org/2000/svg'%20viewBox='0%200%200%200'%3E%3C/svg%3E)
Introduction
Ceftriaxone, sold under the trade name Rocephin, is a third-generation cephalosporin antibiotic commonly used to treat severe urinary tract infections (UTIs), pyelonephritis, and other serious bacterial infections. Its broad-spectrum activity and availability as an injectable make it an excellent choice for inpatient or emergency treatment.
Purpose
- Treats severe UTIs, including pyelonephritis and complicated infections.
- Effective against resistant bacteria in both outpatient and hospital settings.
- Used as a first-line treatment for sepsis or urosepsis stemming from urinary infections.
How It Works
Ceftriaxone works by inhibiting bacterial cell wall synthesis, leading to cell death. Its long half-life allows for once-daily dosing, making it convenient for inpatient and outpatient management.
Usage
- Administered as an intramuscular (IM) or intravenous (IV) injection, typically once daily.
- Dosage and duration depend on the severity of the infection, often ranging from 1-14 days.
- May be used as part of combination therapy for multidrug-resistant infections.
Considerations
- Common side effects include injection site pain, diarrhea, and mild rash.
- Rare but serious risks include severe allergic reactions, biliary sludging, or kidney dysfunction.
- Not recommended for patients with severe penicillin or cephalosporin allergies.
At Crossroads Urology
At Crossroads Urology, Ceftriaxone is utilized for urgent and severe urinary infections. Our providers use it judiciously as part of a comprehensive care plan, often in collaboration with hospital teams for inpatient cases.
Conclusion
Ceftriaxone [Rocephin] is a reliable and powerful antibiotic for treating severe and complicated urinary infections. Contact Crossroads Urology today to learn more about this treatment option and how we can help manage your condition effectively.
